NASDAQ:ORKA Oruka Therapeutics Q2 2026 Earnings Report $97.73 +4.18 (+4.47%) Closing price 09/17/2026 04:00 PM EasternExtended Trading$97.74 +0.02 (+0.02%) As of 09/17/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oruka Therapeutics EPS ResultsActual EPS-$0.55Consensus EPS -$0.51Beat/MissMissed by -$0.04One Year Ago EPSN/AOruka Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOruka Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time7:00AM ETUpcoming EarningsOruka Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Oruka Therapeutics Earnings HeadlinesArjun Agarwal Sells 9,459 Shares of Oruka Therapeutics (NASDAQ:ORKA) StockSeptember 17 at 4:38 AM | americanbankingnews.comJoana Goncalves Sells 7,947 Shares of Oruka Therapeutics (NASDAQ:ORKA) StockSeptember 17 at 4:38 AM | americanbankingnews.com“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11. | Brownstone Research (Ad)Oruka (ORKA): EVERLAST-A 28+ Week Data Key Catalyst For ORKA-001 In PsoriasisSeptember 15 at 2:03 PM | rttnews.comOruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 13, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Jazz Pharmaceuticals (JAZZ)September 10, 2026 | theglobeandmail.comSee More Oruka Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oruka Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oruka Therapeutics and other key companies, straight to your email. Email Address About Oruka TherapeuticsOruka Therapeutics (NASDAQ:ORKA) (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments. Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17. These programs remain in clinical development and have not been approved for commercial use. The company was formed through a business combination involving ARCA biopharma and Oruka Therapeutics and operates as Oruka Therapeutics, Inc. Its activities are focused on advancing its proprietary antibody platform and development programs, primarily for patients with chronic immune-mediated diseases.View Oruka Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Aeluma’s Selloff Could Be Setting Up Its Next Big MoveCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageHoliday Shopping Is Almost Here—And Target May Be Ready to Win BigCan ServisFirst Keep Delivering?Banc of California Bets on Short-Term Pain3 Luxury Consumer Brands to Watch in a Beaten-Down Sector Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
